EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge

Jessica J Harrison, Wilson Nguyen, Mahali S Morgan, Bing Tang, Gervais Habarugira, Henry de Malmanche, Morgan E Freney, Naphak Modhiran, Daniel Watterson, Abigail L Cox, Kexin Yan, Nicholas K Y Yuen und 7 weitere

npj Vaccines · 31.07.2024 · 9 (1)

DOI: 10.1038/s41541-024-00903-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift npj Vaccines, online erschienen am 31.07.2024. Verfasst von Jessica J Harrison und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, 4072, Australia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health | National Health and Medical Research Council (NHMRC), Department of Education and Training | Australian Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2022, a genotype IV (GIV) strain of Japanese encephalitis virus (JEV) caused an unprecedented and widespread outbreak of disease in pigs and humans in Australia. As no veterinary vaccines against JEV are approved in Australia and all current approved human and veterinary vaccines are derived from genotype (G) III JEV strains, we used the recently described insect-specific Binjari virus (BinJV) chimeric flavivirus vaccine technology to produce a JEV GIV vaccine candidate. Herein we describe the production of a chimeric virus displaying the structural prM and E proteins of a JEV GIV isolate obtained from a stillborn piglet (JEV NSW/22 ) in the genomic backbone of BinJV (BinJ/JEV NSW/22- prME). BinJ/JEV NSW/22- prME was shown to be antigenically indistinguishable from the JEV NSW/22 parental virus by K D analysis and a panel of JEV-reactive monoclonal antibodies in ELISA. BinJ/JEV NSW/22- prME replicated efficiently in C6/36 cells, reaching titres of >10 7 infectious units/mL - an important attribute for vaccine manufacture. As expected, BinJ/JEV NSW/22- prME failed to replicate in a variety of vertebrate cells lines. When used to immunise mice, the vaccine induced a potent virus neutralising response against JEV NSW/22 and to GII and GIII JEV strains. The BinJ/JEV NSW/22- prME vaccine provided complete protection against lethal challenge with JEV NSW/22 , whilst also providing partial protection against viraemia and disease for the related Murray Valley encephalitis virus. Our results demonstrate that BinJ/JEV NSW/22- prME is a promising vaccine candidate against JEV.

Autor:innen und Institutionen

  • School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, 4072, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, 4029, Australia.
  • Australian Infectious Disease Research Centre, Brisbane, 4072, 4029, Australia.
  • School of Veterinary Science, The University of Queensland, Gatton, QLD, 4343, Australia.
  • Department of Primary Industries, Elizabeth Macarthur Agricultural Institute, Menangle, NSW, 2568, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, 4029, Australia. daniel.rawle@qimrberghofer.edu.au.

Förderung

  • Department of Health | National Health and Medical Research Council (NHMRC)
  • Department of Education and Training | Australian Research Council

Zitieren

APA

Harrison, J. J., Nguyen, W., Morgan, M. S., Tang, B., Habarugira, G., de Malmanche, H., Freney, M. E., Modhiran, N., Watterson, D., Cox, A. L., Yan, K., Yuen, N. K. Y., Bowman, D. H., Kirkland, P. D., Bielefeldt-Ohmann, H., Suhrbier, A., Hall, R. A., Rawle, D. J., & Hobson-Peters, J. (2024). A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge. npj Vaccines, 9(1). https://doi.org/10.1038/s41541-024-00903-2

Vancouver

Harrison JJ, Nguyen W, Morgan MS, Tang B, Habarugira G, de Malmanche H, et al. A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge. npj Vaccines. 2024;9(1). doi:10.1038/s41541-024-00903-2

BibTeX
@article{Harrison2024,
  author = {Harrison, Jessica J and Nguyen, Wilson and Morgan, Mahali S and Tang, Bing and Habarugira, Gervais and de Malmanche, Henry and Freney, Morgan E and Modhiran, Naphak and Watterson, Daniel and Cox, Abigail L and Yan, Kexin and Yuen, Nicholas K Y and Bowman, Dylan H and Kirkland, Peter D and Bielefeldt-Ohmann, Helle and Suhrbier, Andreas and Hall, Roy A and Rawle, Daniel J and Hobson-Peters, Jody},
  title = {A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge},
  journal = {npj Vaccines},
  year = {2024},
  volume = {9},
  number = {1},
  doi = {10.1038/s41541-024-00903-2}
}
Kostenlos starten →